Compositions and methods for enhancing nk cell activity
AssigneeInnate Pharma
InventorFrancois Romagne
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of treating malignancies and infections, methods of identifying patients suitable for treatment or for inclusion in clinical trials, and methods of producing antibodies for use in therapeutic applications. Generally, the present methods involve the use of antibodies that target activating receptors present on the surface of NK cells, and which at the same time interact with molecules present on the surface of malignant or infected target cells, thereby enhancing the therapeutic efficacy of the antibodies.
Claims25
1-24. (canceled)
A method for producing an antibody suitable for use in treating hematological malignancies, said method comprising a) providing a human-suitable antibody that specifically binds to a human activating NK cell receptor, and b) assessing the ability of said antibody to specifically bind to a human Fc receptor, wherein a determination that said antibody can specifically bind to said receptor indicates that said antibody is suitable for use in treating said malignancies.
A method for treating a patient with a hematological malignancy selected from the group consisting of follicular lymphoma, B cell lymphoma, macrophage tumors, acute monocytic leukemia, chronic myelomonocytic leukemia, chronic lymphocytic leukemia, mast cell malignancy, myeloid metaplasia, and chronic myelocytic leukemia, said method comprising administering to said patient a pharmaceutical composition comprising a human-suitable antibody that specifically binds to a human activating NK cell receptor, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.